Matching articles for "alirocumab"
Issue 1759 · July 20, 2026
Drugs for Hypertriglyceridemia

Adults with persistent fasting triglyceride levels ≥150 mg/dL are considered to have hypertriglyceridemia; when levels are ≥500 mg/dL, it is considered severe. Hypertriglyceridemia is associated with an…

Med Lett Drugs Ther. 2026 Jul 20; 68(1759):117-9 doi:10.58347/tml.2026.1759e
Adults with persistent fasting triglyceride levels ≥150 mg/dL are considered to have hypertriglyceridemia; when levels are ≥500 mg/dL, it is considered severe. Hypertriglyceridemia is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD); severe hypertriglyceridemia increases the risk of acute pancreatitis.
Issue 1756 · June 8, 2026
Drugs for Hypercholesterolemia

Recently published multisociety guidelines for the management of dyslipidemia emphasize early identification and treatment of dyslipidemia to reduce the lifetime risk of atherosclerotic cardiovascular disease…

Med Lett Drugs Ther. 2026 Jun 8; 68(1756):89-95 doi:10.58347/tml.2026.1756a
Recently published multisociety guidelines for the management of dyslipidemia emphasize early identification and treatment of dyslipidemia to reduce the lifetime risk of atherosclerotic cardiovascular disease (ASCVD) and death.
Issue 1756 · June 8, 2026
Comparison Chart: Some Non-Statin Lipid-Lowering Drugs (online only)

View the Comparison Chart: Some Non-Statin Lipid-Lowering Drugs

Med Lett Drugs Ther. 2026 Jun 8; 68(1756):e96-8 doi:10.58347/tml.2026.1756c
View the Comparison Chart: Some Non-Statin Lipid-Lowering Drugs
Issue 1754 · May 11, 2026
Lerodalcibep (Lerochol) for Hypercholesterolemia

The FDA has approved lerodalcibep ( Lerochol – Lib Therapeutics), a subcutaneously injected proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, to reduce low-density lipoprotein cholesterol…

Med Lett Drugs Ther. 2026 May 11; 68(1754):73-5 doi:10.58347/tml.2026.1754a
The FDA has approved lerodalcibep ( Lerochol – Lib Therapeutics), a subcutaneously injected proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Lerodalcibep is the fourth subcutaneously injected PCSK9-directed therapy to be approved in the US; the monoclonal antibodies alirocumab (Praluent) and evolocumab (Repatha) and the small interfering RNA inclisiran (Leqvio) were approved earlier (see Table 3)
Issue 1745 · January 5, 2026 Free
Correction

In our recent article titled Expanded Indication for PCSK9 Inhibitors (Med Lett Drugs Ther 2025; 67:201), the number needed to treat (NNT) to prevent one composite endpoint of myocardial infarction, ischemic…

Med Lett Drugs Ther. 2026 Jan 5; 68(1745):8 doi:10.58347/tml.2026.1745e
In our recent article titled Expanded Indication for PCSK9 Inhibitors (Med Lett Drugs Ther 2025; 67:201), the number needed to treat (NNT) to prevent one composite endpoint of myocardial infarction, ischemic stroke, or death from coronary heart disease in the VESALIUS-CV trial was incorrectly stated as 5 instead of 56. A corrected version of the article appears online:
Issue 1744 · December 22, 2025
Expanded Indication for PCSK9 Inhibitors

The FDA has approved changes to the wording of the cardiovascular risk reduction indications for the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab (Repatha) and alirocumab…

Med Lett Drugs Ther. 2025 Dec 22; 67(1744):201-3 doi:10.58347/tml.2025.1744a
The FDA has approved changes to the wording of the cardiovascular risk reduction indications for the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab (Repatha) and alirocumab (Praluent) . Both drugs are now approved to reduce the risk of major adverse cardiovascular events (MACE) in adults at increased risk for these events; they were previously approved to reduce the risk of MACE only in patients with established cardiovascular disease (CVD).
Issue 1737 · September 15, 2025
Inclisiran (Leqvio) Monotherapy for LDL-Cholesterol Reduction

Inclisiran ( Leqvio – Novartis), a subcutaneously injected small interfering RNA (siRNA) that decreases LDL-cholesterol (LDL-C) levels by reducing synthesis of proprotein convertase subtilisin/kexin type 9…

Med Lett Drugs Ther. 2025 Sep 15; 67(1737):148-9 doi:10.58347/tml.2025.1737c
Inclisiran ( Leqvio – Novartis), a subcutaneously injected small interfering RNA (siRNA) that decreases LDL-cholesterol (LDL-C) levels by reducing synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9), has been approved by the FDA for use with or without a statin to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Inclisiran had previously been approved for use only in combination with statin therapy.
Issue 1702 · May 13, 2024
A New Indication for Bempedoic Acid (Nexletol)

The oral adenosine triphosphate-citrate lyase (ACL) inhibitor bempedoic acid was approved by the FDA in 2020 for use alone ( Nexletol – Esperion) and in a fixed-dose combination with the cholesterol…

Med Lett Drugs Ther. 2024 May 13; 66(1702):75-7 doi:10.58347/tml.2024.1702b
The oral adenosine triphosphate-citrate lyase (ACL) inhibitor bempedoic acid was approved by the FDA in 2020 for use alone ( Nexletol – Esperion) and in a fixed-dose combination with the cholesterol absorption inhibitor ezetimibe (Nexlizet) as an adjunct to maximally tolerated statin therapy in adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-cholesterol (LDL-C) lowering. The indication has now been expanded to include reducing the risk of myocardial infarction (MI) and coronary revascularization in adults with established cardiovascular disease (CVD) or at high risk for a CVD event who are unable to take recommended statin therapy.
Issue 1674 · April 17, 2023 Free
In Brief: Cardiovascular Outcomes with Bempedoic Acid (Nexletol)

Since our initial review of the oral lipid-lowering adenosine triphosphate-citrate lyase (ACL) inhibitor bempedoic acid ( Nexletol – Esperion) in 2020, cardiovascular outcomes data in statin-intolerant…

Med Lett Drugs Ther. 2023 Apr 17; 65(1674):62-3 doi:10.58347/tml.2023.1674b
Since our initial review of the oral lipid-lowering adenosine triphosphate-citrate lyase (ACL) inhibitor bempedoic acid ( Nexletol – Esperion) in 2020, cardiovascular outcomes data in statin-intolerant patients have become available.
Issue 1659 · September 19, 2022
Comparison Table: Some Lipid-Lowering Drugs (online only)

View the Comparison Table: Some Lipid-Lowering Drugs

Med Lett Drugs Ther. 2022 Sep 19; 64(1659):e152-6
View the Comparison Table: Some Lipid-Lowering Drugs
Issue 1659 · September 19, 2022
Lipid-Lowering Drugs

Cholesterol management guidelines from the American College of Cardiology/American Heart Association Task Force were last published in 2019.

Med Lett Drugs Ther. 2022 Sep 19; 64(1659):145-52
Cholesterol management guidelines from the American College of Cardiology/American Heart Association Task Force were last published in 2019.
Issue 1646 · March 21, 2022
Inclisiran (Leqvio) for LDL-Cholesterol Lowering

The FDA has approved inclisiran ( Leqvio – Novartis), a small interfering RNA (siRNA) directed to proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA, as an adjunct to diet and maximally tolerated…

Med Lett Drugs Ther. 2022 Mar 21; 64(1646):43-5
The FDA has approved inclisiran ( Leqvio – Novartis), a small interfering RNA (siRNA) directed to proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA, as an adjunct to diet and maximally tolerated statin therapy for subcutaneous (SC) treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of low-density lipoprotein cholesterol (LDL-C). Inclisiran is the first FDA-approved PCSK9-directed siRNA therapeutic agent.
Issue 1623 · May 3, 2021
Evinacumab (Evkeeza) for Homozygous Familial Hypercholesterolemia

The FDA has approved evinacumab-dgnb ( Evkeeza – Regeneron), an angiopoietin-like 3 (ANGPTL3) inhibitor, for adjunctive IV treatment of homozygous familial hypercholesterolemia (HoFH) in patients ≥12 years…

Med Lett Drugs Ther. 2021 May 3; 63(1623):66-7
The FDA has approved evinacumab-dgnb ( Evkeeza – Regeneron), an angiopoietin-like 3 (ANGPTL3) inhibitor, for adjunctive IV treatment of homozygous familial hypercholesterolemia (HoFH) in patients ≥12 years old. Evinacumab is the first ANGPTL3 inhibitor to be approved in the US.
Issue 1595 · April 6, 2020
Bempedoic Acid (Nexletol) for Lowering LDL-Cholesterol

The FDA has approved the oral adenosine triphosphate-citrate lyase (ACL) inhibitor bempedoic acid for use alone ( Nexletol – Esperion) and in a fixed-dose combination with the cholesterol absorption…

Med Lett Drugs Ther. 2020 Apr 6; 62(1595):53-5
The FDA has approved the oral adenosine triphosphate-citrate lyase (ACL) inhibitor bempedoic acid for use alone ( Nexletol – Esperion) and in a fixed-dose combination with the cholesterol absorption inhibitor ezetimibe (Nexlizet) as an adjunct to diet and maximally tolerated statin therapy in adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-cholesterol (LDL-C). Bempedoic acid is the first ACL inhibitor to be approved in the US.
Issue 1565 · February 11, 2019
Lipid-Lowering Drugs

Cholesterol management guidelines from the American College of Cardiology/American Heart Association Task Force have recently been published. See Table 1 for a brief summary of their recommendations.

Med Lett Drugs Ther. 2019 Feb 11; 61(1565):17-24
Cholesterol management guidelines from the American College of Cardiology/American Heart Association Task Force have recently been published. See Table 1 for a brief summary of their recommendations.
Issue 1565 · February 11, 2019
Expanded Table: Lipid-Lowering Drugs (online only)

View the Expanded Table: Lipid-Lowering Drugs

Med Lett Drugs Ther. 2019 Feb 11; 61(1565):e24-30
View the Expanded Table: Lipid-Lowering Drugs
Issue 1519 · April 24, 2017
Reduction of Cardiovascular Risk with Evolocumab (Repatha)

The results of the recently published FOURIER trial have shown a reduction in cardiovascular events with addition of the PCSK9 inhibitor evolocumab (Repatha) to statin therapy in patients with atherosclerotic…

Med Lett Drugs Ther. 2017 Apr 24; 59(1519):63-4
The results of the recently published FOURIER trial have shown a reduction in cardiovascular events with addition of the PCSK9 inhibitor evolocumab (Repatha) to statin therapy in patients with atherosclerotic cardiovascular disease (ASCVD).
Issue 1506 · October 24, 2016
Lipid-Lowering Drugs

Lipid-lowering drugs should be taken indefinitely; when they are stopped, plasma lipoproteins return to pretreatment levels. HMG-CoA reductase inhibitors (statins) remain the drugs of choice for treatment of…

Med Lett Drugs Ther. 2016 Oct 24; 58(1506):133-40
Lipid-lowering drugs should be taken indefinitely; when they are stopped, plasma lipoproteins return to pretreatment levels. HMG-CoA reductase inhibitors (statins) remain the drugs of choice for treatment of most patients who require lipid-lowering therapy.
Issue 1503 · September 12, 2016 Free
In Brief: Repatha Pushtronex - A New Evolocumab Injection Device

The PCSK9 inhibitor evolocumab ( Repatha – Amgen) is now available in a single-dose, hands-free device (Repatha Pushtronex) for once-monthly subcutaneous infusion. Evolocumab is FDA-approved as an adjunct to…

Med Lett Drugs Ther. 2016 Sep 12; 58(1503):120
The PCSK9 inhibitor evolocumab ( Repatha – Amgen) is now available in a single-dose, hands-free device (Repatha Pushtronex) for once-monthly subcutaneous infusion. Evolocumab is FDA-approved as an adjunct to diet and maximally tolerated statin therapy for patients with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease who require additional lowering of low-density lipoprotein cholesterol (LDL-C), and as an adjunct to diet and other LDL-lowering therapies for patients with homozygous familial hypercholesterolemia (HoFH). Evolocumab is also available in 140-mg single-use prefilled syringes and autoinjectors (Repatha Sureclick) . 1 Use of these formulations to administer the once-monthly dose (420 mg) requires patients to inject themselves three consecutive times within 30 minutes. Another PCSK9 inhibitor, alirocumab (Praluent) , is injected every 2 weeks; it is available in single-dose prefilled syringes and pens. The Repatha Pushtronex system consists of a single-use, battery-powered infusor and a prefilled cartridge containing a 420-mg dose of evolocumab. Once assembled, the patient adheres the device to the skin of the abdomen, thigh, or upper arm and presses a button to begin the subcutaneous injection; infusion of the dose takes about 9 minutes. One Repatha Pushtronex device costs $1175. Three 140-mg Repatha Sureclick autoinjectors or Repatha prefilled syringes cost $1627. 2 Evolocumab (Repatha) – a second PCSK9 inhibitor to lower LDL-cholesterol. Med Lett Drugs Ther 2015; 57:140. Approximate WAC for one 420-mg dose. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. August 5, 2016. Reprinted with permission by First Databank, Inc. All rights reserved. ©2016. www.fdbhealth.com/policies/drug-pricing-policy. Download complete U.S. English article
Issue 1479 · October 12, 2015
Evolocumab (Repatha) - A Second PCSK9 Inhibitor to Lower LDL-Cholesterol

Evolocumab ( Repatha – Amgen), a subcutaneously injected PCSK9 inhibitor, has been approved by the FDA as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial…

Med Lett Drugs Ther. 2015 Oct 12; 57(1479):140-1
Evolocumab ( Repatha – Amgen), a subcutaneously injected PCSK9 inhibitor, has been approved by the FDA as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease who require additional lowering of LDL-cholesterol (LDL-C). It was also approved as an adjunct to diet and other LDL-lowering therapies in patients with homozygous familial hypercholesterolemia (HoFH) who require additional lowering of LDL-C. Evolocumab is the second PCSK9 inhibitor to be approved in the US; alirocumab (Praluent) was approved earlier.
Issue 1475 · August 17, 2015
Alirocumab (Praluent) to Lower LDL-Cholesterol

The FDA has approved the subcutaneously injected PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor alirocumab ( Praluent – Sanofi/Regeneron) as an adjunct to diet and maximally tolerated statin…

Med Lett Drugs Ther. 2015 Aug 17; 57(1475):113-5
The FDA has approved the subcutaneously injected PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor alirocumab ( Praluent – Sanofi/Regeneron) as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease who require additional lowering of LDL-cholesterol (LDL-C). It was not approved for general use in statin-intolerant patients. Alirocumab is the first PCSK9 inhibitor to be approved in the US. Evolocumab ( Repatha – Amgen), another PCSK9 inhibitor, was recently approved in Europe and has been recommended for approval for the same indications in the US by an FDA Advisory Committee.